Anti-Obesity Agent

DENVER — Losing weight is good for patients’ wallets as well as their health, according to a presenter at the Obesity Medicine Association’s annual conference.

Hundreds of clinicians will gather in Denver next week to discuss the latest treatment strategies and evidence-based approaches to obesity management.

DALLAS — New data presented at ObesityWeek demonstrate an encouraging early profile of an investigational dual GLP-1/GIP receptor agonist in healthy adults, according to a speaker at ObesityWeek.

In response to controversial study data on the efficacy of colonoscopies, Nadeem Baig, MD, stressed that they are effective at saving lives when performed.

There are seven different anti-obesity medications that are approved in the United States and a number of others that are used off label, most commonly metformin, according to Jennifer C. Seger, MD, FOMA, ABFM, ABOM.

Use of GLP-1 receptor agonists for treatment of diabetes or obesity does not increase the risk for breast cancer or benign breast neoplasms, according to study findings.

Adults with obesity who continued once-weekly semaglutide therapy beyond 20 weeks saw continued weight loss or weight maintenance compared with adults who were switched to placebo, data from the STEP 4 study show.

Obesity, recognized as a chronic medical condition, affects more than 30% of adults in the United States and directly contributes to increased risk for CVD.